Navigating Reimbursement Feasibility for Innovative medical devices in the field of complex PCI

In this case study, we navigated intricate reimbursement landscapes for a pioneering medical device company focused on advanced medical devices for the treatment of complex PCI.

Crafting an Effective Reimbursement Feasibility Strategy:

Our collaboration centered on providing a comprehensive reimbursement feasibility study across Germany, France, and the UK. The study aimed to address critical queries for each country, including:

 • Product Coding and Payment Scheme

 • Coverage and coding for the new or similar procedure

 • Process for creation of New Reimbursement Codes

 • Applicability of Innovative Technology Reimbursement Programs

 • Clinical and Economic Evidence Requirements (Short and Long-Term)

 • HTA-Centric Clinical Value Proposition

 • Short and long-term reimbursement strategies

 • Country Prioritization

Analyzing Clinical and Economic Benefits: 

 We initiated by analyzing the current patient management with antithrombotic and dual antiplatelet therapies post-PCI and assessing coverage of associated complications. This evaluation determined the clinical and economic benefits of integrating the product into national healthcare systems.

Holistic Approach to Reimbursement: 

By meticulously reviewing national health authorities' recommendations and medical societies' guidelines, we defined the product's position in therapeutic disease management and the necessary requisites for successful reimbursement. Interviews with national authorities and KOLs further enriched our insights.

Comprehensive Reimbursement Insights:

Building upon our understanding of healthcare reimbursement dynamics, we delivered:

 • Applicable Reimbursement Scheme Analysis

 • Coding and Coverage Information

 • Specific clinical and economic evidence requirements

 • Actionable short- and long-term strategies

 • Prioritized Roadmap for Country Implementation